Biologicals in practice: Prospective cohort monitoring of high need psoriasis patients;'Biologicals' in de praktijk: Prospectieve cohortmonitoring van 'high need' psoriasispatiënten

Nederlands Tijdschrift voor Dermatologie en Venereologie

Volumn 17, Issue 5, 2007, Pages 162-166

  Driessen, R J B ^a   Berends, M A M ^a   Van De Kerkhof, P C M ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biological; Prospective cohort study

Indexed keywords

DITHRANOL; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D DERIVATIVE;

ACTINIC KERATOSIS; ARTHRALGIA; BASAL CELL CARCINOMA; CONFERENCE PAPER; DYSPNEA; EDEMA; EPISTAXIS; ESOPHAGUS CARCINOMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOGLYCEMIA; INFECTION; INJECTION SITE REACTION; PROSPECTIVE STUDY; PRURITUS; PSORIASIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

EID: 34447553551     PISSN: 09258604     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
2. Richtlijn: Het toepassen van biologicals in de behandeling van patiënten met plaque psoriasis. www.huidziekten.nl/ richtlijnen/ nvdvbiologicals2005concept.doc.
3. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12.
4. BerendsMAM, DriessenRJB, LangewoutersAMG, Boezeman JB, Van de Kerkhof PCM, De Jong EMGJ. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat april 2007; in press.
5. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32.
6. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
7. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12.
8. de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006;155:808-14.
9. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arteritis: a prospective study. Arthritis Res Ther 2005;7: R666-76.